Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · IEX Real-Time Price · USD
39.42
-0.18 (-0.45%)
Jun 24, 2024, 4:00 PM EDT - Market closed
-0.45%
Market Cap 3.57B
Revenue (ttm) 442.59M
Net Income (ttm) -613.35M
Shares Out 90.57M
EPS (ttm) -7.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 782,803
Open 39.71
Previous Close 39.60
Day's Range 39.13 - 40.30
52-Week Range 31.52 - 54.56
Beta 0.60
Analysts Strong Buy
Price Target 86.80 (+120.19%)
Earnings Date Aug 1, 2024

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and ad... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 1,276
Stock Exchange NASDAQ
Ticker Symbol RARE
Full Company Profile

Financial Performance

In 2023, RARE's revenue was $434.25 million, an increase of 19.52% compared to the previous year's $363.33 million. Losses were -$606.64 million, -14.25% less than in 2022.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price forecast is $86.8, which is an increase of 120.19% from the latest price.

Price Target
$86.8
(120.19% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...

4 days ago - GlobeNewsWire

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

10 days ago - GlobeNewsWire

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

12 days ago - GlobeNewsWire

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval

12 days ago - GlobeNewsWire

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

14-month data show treatment with setrusumab resulted in  a large, sustained 67% reduction in annualized fracture rate  and persistent median annualized fracture rate of 0.00 (p=0.0014)

13 days ago - GlobeNewsWire

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

20 days ago - GlobeNewsWire

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p

25 days ago - GlobeNewsWire

Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference

NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...

6 weeks ago - GlobeNewsWire

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million

7 weeks ago - GlobeNewsWire

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company's efforts to trans...

7 weeks ago - GlobeNewsWire

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser...

2 months ago - GlobeNewsWire

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif.

2 months ago - GlobeNewsWire

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome Company will host investor call on April 17 at ...

2 months ago - GlobeNewsWire

Ultragenyx to Participate at Investor Conferences in March

44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 202...

4 months ago - GlobeNewsWire

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue...

4 months ago - GlobeNewsWire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

4 months ago - GlobeNewsWire

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024 The latest data from the pivotal Transpher A and long-term follow-up studies will...

4 months ago - GlobeNewsWire

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected in first half of 2024 NOVATO, Calif., Feb. 05, 2024 (G...

5 months ago - GlobeNewsWire

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWS...

5 months ago - GlobeNewsWire

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

Preliminary 2023 Total Revenue of $430 million to $435 million,  Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million

6 months ago - GlobeNewsWire

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final dra...

6 months ago - GlobeNewsWire

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024 Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half ...

6 months ago - GlobeNewsWire

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

6 months ago - GlobeNewsWire

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterol For the first time, paedi...

6 months ago - GlobeNewsWire

Ultragenyx to Participate at Investor Conferences in November

6 th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx...

7 months ago - GlobeNewsWire